Skip to Content

InteRVENE study

  • Principal Investigator/s: Prof Mary Ward


  • Name of the Study: Intervention with Riboflavin to improve Vascular health and ENdothelial functioning in Genetically at- risk adults (InteRVENE study)


  • Why is this Study important? Around 10% of the world’s population have a particular genetic make-up (known as the TT genotype) that may increase the risk of having high blood pressure (hypertension). Our research group has previously reported that a B-vitamin riboflavin can decrease blood pressure in adults with this genetic risk. Whether B-vitamins can also improve blood vessel function, an important predictor of cardiovascular health is not known. Also, the effects of short-term (4 and 8 weeks) riboflavin supplementation and different riboflavin doses on blood pressure and blood vessel function is not known.


  • What is the Research question/aim?: This study aims to examine whether riboflavin supplementation at different doses can lower blood pressure and improve blood vessel function in adults screened for the TT genotype.


  • What the Study involves: This study will last for 16 weeks, with four separate study visits at weeks 0, 4, 8 and 16. Each participant will be asked to complete a survey which includes life and health style questionnaire as well as the International Physical Activity Questionnaire (IPAQ).


  • PPI Involvement: We routinely engage with our participants to disseminate results and to get input on practical aspects of study design. Our PPI group also provide valuable feedback on out participant information sheets.


  • Who can take part in the Study? This study aims to recruit Male adults between the ages of 18 and 60 who are not currently taking B-vitamin supplement who have had their MTHFR genotype sequenced from a previous research study.
  • Contact Information:

Researcher: Ryan Barlow


PI: Professor Mary Ward





NI Clinical Research Facility,
U Floor, Belfast City Hospital,
Lisburn Road, Belfast, BT9 7AB

Tel:+44 (0)28 9504 0342

Connect to the NICRF